A SERM increasing the expression of the osteoblastogenesis and mineralization-related proteins and improving quality of bone tissue in an experimental model of osteoporosis Raloxifene is an antiresorptive drug, selective estrogen receptor modulator 
Introduction
Post-menopausal osteoporosis is the main skeletal disorder with high incidence found in society, being characterized by reduced bone mass due to estrogen deficiency and decreased intestinal absorption of calcium, resulting in increased bone fragility and fracture susceptibility 19 . The animals were divided into three groups: SHAMrats submitted to sham surgery and fed a balanced diet; OVX -rats submitted to bilateral ovariectomy and fed a low calcium diet (osteoporotic) without medical treatment; RLX -rats submitted to bilateral ovariectomy and fed a low calcium diet (osteoporotic) with raloxifene treatment.
The animals were kept in cages and fed a balanced diet (NUVILAB, Curitiba, PR, Brazil) containing 1.4% Ca ++ and 0.8% P, and given water ad libitum. After completion of sham surgeries and ovariectomies, animals in the SHAM group continued to receive rations of the balanced diet, whereas animals in the other two groups were switched to a diet containing 0.1% Ca ++ and 0.5% P (RHOSTER Ind. Com., Vargem Grande Paulista, SP, Brazil).
Estrous cycle classification
The rats were placed in individual cages for daily This fact confirmed the presence of osteopenia in the latter group, which is characteristic of the osteoporotic rat model.
Bilateral ovariectomy
RLX and OVX rats were anesthetized, and incisions in both flanks were subsequently performed to expose the ovaries, which were then surgically removed. Rats from the SHAM group were subjected to the same procedure. However, the ovaries were exposed and not removed. 
Micro CT -description of two-dimensional (2D) and three-dimensional (3D) morphometric calculations
The parameters used in this study were adopted in accordance with the guide for evaluation of bone microarchitecture in rodents using micro computed tomography. 1 CTAnalyzer software (Skyscan, Leuven, Belgium) was used to perform 2D and 3D morphometry. From that first demarcation, two new rectangular areas occupying the same regions of the implant were demarcated at 50 slices in the proximal and distal directions relative to the bone where the implant was installed, thus a total volume of 100 slices (874.3 μm) was examined.
After ROI standardization, the sequence of images was converted to grayscale by using a scale ranging from 0 to 255, with a minimum value of 70 and a maximum value of 100 in all groups. These amounts were determined based on the visualization of the cancellous bone structure, located in the region of interest.
Micro-tomography parameters analyzed were bone 
Results

Immunohistochemical analysis
In general, the β-catenin, Wnt, and RUNX2
proteins that indicate the presence of osteogenic cell differentiation showed greater labeling for RLX groups when compared with OVX groups, regardless period of analysis (14 and 42 days postoperatively), but not for RUNX2 at 42 days, which showed mild labeling.
Concerning the mineralization proteins (osteopontin and osteocalcin) for both periods, RLX groups showed moderate labeling whereas OVX groups showed mild labeling.
Molecular (PCR) analysis
The gene expression of osteocalcin and ALP showed higher values for RLX group (P<0.05), followed by For BSP data, the highest expression was observed in RLX groups and the lowest expression, in OVX groups 
3D radiographic evaluation (Micro-CT)
Regarding the bone volume, we observed that RLX group tended to have higher bone volume values, followed by OVX and SHAM groups, as noted by the mean shown in the chart. However, there was no statistically significant difference between the groups (P>0.05) ( Figure 7) .
As for the total bone porosity, RLX group had statistically significant lower total bone porosity than Values of closed pores surface were higher for SHAM group followed by OVX and RLX groups (P<0.05) ( Figure 8F ).
Regarding the porosity open (Po.V and Po), we observed higher values for SHAM group followed by OVX and RLX groups (P<0.05) (Figures 8G and H) .
As for SMI data, RLX group showed values closer to zero, while SHAM group showed values closer to three, which means more parallel trabeculae and higher bone density (P<0.05) (Figure 9 ).
Discussion
We suggested that raloxifene can stimulate the growing of pre-osteoblastics cells and promote the mineralization of bone extracellular matrix by increasing the immunolabeling of osteoblastogenesis- Experimental studies showed that raloxifene was able to optimize wound healing in rats with induced osteoporosis, relative to both hormone replacement therapy 13-15,17 and alendronate therapy 16, 18 .
Recently, the importance of canonical Wnt/β-catenin signaling in the pathogenesis of bone tissue was highlighted due to the discovery of mutations which be explained by the fact that RUNX2 acts at the start of osteoblast differentiation, with a peak at 14 days.
However, Wnt/β-catenin levels showed that raloxifene treatment stimulated the osteoblastic differentiation process, and consequently bone formation, around the tibial implants, compared to the ovariectomized animals that received no treatment, which showed low osteoblastic activity.
Despite the benefits of the drug regarding osteoblastic activity, it is important that the neo-formed This study showed that there was an increasing labeling of osteocalcin and osteopontin in the RLX group both at 14 and at 42 days, in contrast to the OVX group, which showed mild expression in both periods. Osteopontin levels were found to be balanced across all groups at all time points. The positive effect of the drug is even more evident when associating immunohistochemical findings to data obtained by micro-CT, which uncovered increased bone volume in the RLX group compared to the OVX group. This is corroborated by previous studies in animals 24 ,
and although there was no statistically significant difference, the results allow us to state that the drug provided fundamental characteristics for the success of peri-implant repair.
Other proteins related to mineralization of bone metabolism, such as BSP and ALP, showed greater gene expression for RLX and SHAM groups compared to OVX groups. Thus, it was clear that the biological behavior of bone healing in osteoporotic rats treated with RLX was very similar to the healthy rats (SHAM).
This drug was able to recover some poor quality of bone tissue observed in OVX rats with no treatment.
The amount of porosity and trabeculae geometry was analyzed in this study and demonstrates the quality of bone tissue microarchitecture. In this way, an increase of porosity parameters shows a decreasing of bone quality a weight gain in the animals that received raloxifene.
However, further studies of our team are being perform, aiming to show not only the local effect of osteoporosis drugs (raloxifene, strontium ranelate, PTH), but the systemic effect of these drugs and whether they show any adverse effect.
Conclusions
Regarding these findings, and despite all limitations of this study, it is possible to conclude that raloxifene treatment in ovariectomized rats provided a positive effect on tibial peri-implant repair by stimulating We also demonstrated that, by investigating bone matrix mineralization and microarchitecture characteristics, this newly formed bone is of high quality. We therefore believe that raloxifene must be considered in the treatment of osteoporosis, not only for its benefits in preventing fractures, but also as an adjunct in the dental implant rehabilitation process.
